<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30460464</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-7217</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>20</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research and treatment</Title>                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>            </Journal>            <ArticleTitle>Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-5040-3</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since concurrent malignancy may be associated with radial scars (RS) in up to 45% of RS diagnosed on core biopsy, surgical excision is usually advised. Recent very low upgrade rates have caused a re-evaluation of the need for routine surgery. We aimed to find subsets of RS at such low risk of upgrade, as to render imaging surveillance a plausible alternative to surgery.</AbstractText>                <AbstractText Label="DESIGN" NlmCategory="METHODS">We performed a systematic review of the Pubmed, Cochrane and Embase databases, focusing on the following eligibility criteria: full papers, published after 1998, in English, included at least 5 RS, provided information on needle biopsy gauge and upgrade rates based on the excised lesion. For the meta-analysis, studies were grouped by the presence of histologic atypia and the core needle gauge. Study-specific and pooled upgrade rates were calculated for each subgroup.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">49 studies that included 3163 RS with surgical outcomes are included. There were 217 upgrades to malignancies, 71 (32.7%) invasive and 144 (66.4%) DCIS. The random-effects pooled estimate was 7% (95% CI 5, 9%). Among the pre-planned subgroups, in RS assessed by 14G NCB the upgrade rates were: without atypia - 5% (95% CI 3, 8%), mixed or presence of atypia not specified - 15% (95% CI 10, 20%), with atypia - 29% (95% CI 20, 38%). For RS assessed by a mix of 8-16G cores the respective upgrade rates were 2% (95% CI 1, 4%), 12% (95% CI 6, 18%) and 11% (95% CI 3, 23%) and for RS assessed by 8-11 vacuum assisted biopsies 1% (95% CI 0, 4%), 5% (95% CI 0, 11%) and 18% for the one study of RS with atypia assessed by VAB. Surgery after VAB excision showed no upgrades. The difference across all subgroups was statistically significant.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">When stratified by atypia and biopsy gauge, upgrade rates in RS are consistent and predictable. RS assessed by VABs and lacking atypia have a 1% (95% CI 0, 4%) upgrade rate to DCIS. Other groups have upgrade rates of 2-28%. This risk may be reduced by VAB excision. The results of this meta-analysis provide a decision aid and evidence-based selection criteria for surgery after a needle biopsy diagnosis of RS.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Farshid</LastName>                    <ForeName>Gelareh</ForeName>                    <Initials>G</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2056-0561</Identifier>                    <AffiliationInfo>                        <Affiliation>South Australian Pathology, Royal Adelaide Hospital, Adelaide, SA, Australia. gelareh.farshid2@sa.gov.au.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>BreastScreen South Australia, Flinders Street, Adelaide, SA, Australia. gelareh.farshid2@sa.gov.au.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Discipline of Medicine, Adelaide University, North Terrace, Adelaide, SA, Australia. gelareh.farshid2@sa.gov.au.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Buckley</LastName>                    <ForeName>Elizabeth</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Epidemiology and Population Health Research Group, University of South Australia, Adelaide, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Breast Cancer Res Treat</MedlineTA>            <NlmUniqueID>8111104</NlmUniqueID>            <ISSNLinking>0167-6806</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Core biopsy</Keyword>            <Keyword MajorTopicYN="N">Mammography</Keyword>            <Keyword MajorTopicYN="N">Radial scar</Keyword>            <Keyword MajorTopicYN="N">Screening</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>20</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>11</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30460464</ArticleId>            <ArticleId IdType="doi">10.1007/s10549-018-5040-3</ArticleId>            <ArticleId IdType="pii">10.1007/s10549-018-5040-3</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>